|
Craig Tooman has served as Enzon’s executive vice president of finance and chief financial officer since, 2005. In this role, he is responsible for all financial aspects of Enzon, in addition to the Company’s investor relations, public relations, and strategic planning functions. Mr. Tooman joined Enzon in January 2005 as the Company’s executive vice president of strategic planning and corporate communications.
Mr. Tooman has nearly 20 years of industry experience, having worked extensively in diverse pharmaceutical positions including investor communications, strategic planning, finance, marketing, and sales. Prior to joining Enzon, he served as senior vice president of strategic planning and corporate communications of ILEX Oncology, Inc, which was acquired by Genzyme in December 2004.
While at ILEX, Mr. Tooman managed the formation of ILEX’s first comprehensive strategic plan and the restructuring of the company’s clinical development activities to drive the company’s transformation from a drug development contract research organization into a product-driven pharmaceutical company. Mr. Tooman was also responsible for managing ILEX’s investment banking relationships, including playing a critical role in the merger of ILEX and Genzyme, a $1 billion transaction.
Before joining ILEX, Mr. Tooman worked at Pharmacia Corporation where he progressed through positions of increasing responsibility in investor relations, including vice president of investor relations. In this role, he was responsible for global investor relations activities and spearheaded communications with the financial community on the Pharmacia and Upjohn/Monsanto merger. Additionally, under his leadership the Investor Relations unit of Pharmacia won four of the largest awards of distinction in Investor and Public Relations. He has also held various management positions in Europe and Japan.
Mr. Tooman received his B.A. in economics from Kalamazoo College and an M.B.A. in finance from the University of Chicago. | 